A comprehensive update on clinical and basic aspects of diabetic nephropathy

Diabetes and the Kidney

Editors
K.N. Lai
S.C.W. Tang

Caused by an epidemic increase in obesity and diabetes and metabolic syndromes, diabetic nephropathy has become a leading cause of end-stage renal disease in many developed countries. The publication at hand provides a concise overview of the current state of clinical and basic research in the field. It starts with a summary of the epidemiology and genetics of diabetic nephropathy in different ethnic groups, followed by a review of its clinical manifestation, the link with the metabolic syndrome and obesity, and the pathology of diabetic nephropathy. Building on this basis, the latest findings on pathogenetic, epigenetic and inflammatory mechanisms are presented. The publication also looks at advances in the areas of tubulopathy and the kallikrein-kinin system as well as at the latest animal models and the role of lipoproteins and proteomics. This is followed by a discussion of promising therapeutic approaches such as experimental anti-fibrotic strategies, stem cell therapy and pancreatic transplantation; expert reviewers on the emerging entity of new onset diabetes after transplantation and the preventive strategies for diabetic nephropathy conclude the material presented.

Written by a panel of leading international experts, this book is highly recommended for nephrologists, diabetologists, internists, transplant physicians, scientists, geneticists, epidemiologists and stem cell biologists working in the field of diabetic nephropathy.

www.karger.com/conep

Contents

Preface: Lai, K.N.; Tang, S.C.W.

Clinicopathological Features of Diabetic Nephropathy

Epidemiology of Diabetic Nephropathy: Reutens, A.T.; Atkins, R.C.

Genetics of Diabetic Nephropathy in Diverse Ethnic Groups: Brorsson, C.; Pociot, F.

Clinical Manifestation and Natural History of Diabetic Nephropathy: Ritz, E. et al.

Obesity, Metabolic Syndrome and Diabetic Nephropathy: McE, C.; Hall, J.E.

Pathology of Human Diabetic Nephropathy: Najafian, B. et al.

Pathogenetic Mechanisms of Diabetic Nephropathy

Pathogenesis and Progression of Proteinuric: Thomas, M.C.

Epigenetic Mechanisms: Villeneuve, L.M.; Natarajan, R.

Advanced Glycation End-Products: Thomas, M.C.

Transforming Growth Factor-β and Smads: Lun, H.Y.; Chung, A.C.K.

Angiogenic Factors: Khoury, C.C.; Ziyadeh, F.N.

Endothelial Nitric Oxide Synthase: Nakaqawa, T.; Johnson, R.J.

Reactive Oxygen Species and Oxidative Stress: Noh, H.; Ha, H.

Inflammatory Pathways: Navarro-González, J.F.; Moreno-Fernández, C.


Translating Experimental Diabetic Nephropathy Studies from Mice to Men: Breuer, M.D.

Role of Triglyceride-Rich Lipoproteins in Renal Injury: Ng, K.F. et al.

The Study of Diabetic Nephropathy in the Proteomic Era: Thongboonkerd, V.

Therapeutic Approach of Diabetic Nephropathy

Treatment and Landmark Clinical Trials for Renoprotection: Ting, R.Z.W. et al.

Intensive Glycemic Control and Renal Outcome: Jun, M. et al.


Antifibrotic Treatment and Other New Strategies for Improving Renal Outcomes: Mathew, A. et al.

Kidney Regeneration: Any Prospects? Romagnani, P.

Effects of Pancreas Transplantation on the Prevention and Reversal of Diabetic Nephropathy: Fioretto, P.; Mauer, M.

Prevention of Diabetic Nephropathy

New-Onset Diabetes and Nephropathy after Renal Transplantation: Guiard, J. et al.

Into the Future: Prevention of Diabetes: Bogaert, Y.E.; Schrier, R.W.
CardioRenal Medicine

Guidelines for Authors

Submission

‘CardioRenal Medicine’ only accepts online submissions to:
http://mc.manuscriptcentral.com/crm

All further technical instructions can be found there.

Conditions

The journal will not publish articles which have been previously reported at any length or articles being considered for publication elsewhere. The authors must include a statement to this effect in their cover letter. If publication of the data in any form has occurred or is being contemplated, a copy of such publication should be included with the submitted manuscript. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. The manuscript should be written in English and the editors reserve the right to make appropriate corrections in grammar and style. Accepted papers become the permanent property of ‘CardioRenal Medicine’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. Information concerning financial disclosures (i.e. grants, funding, support, etc.) should be placed at the foot of the title page.

Types of Articles for Acceptance

1 Original Papers: Representing full sets of completed experiments in the areas of either clinical or basic research that answer a given question. Max. 3,000 words, incl. figures, tables. Maximum 25 references.
2 Reviews: Covering a timely topic by experts in the field. Max. 4,500 words, incl. figures, tables. Maximum 60 references.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, a short title for use as running head, conflict of interest statement, and word count. Manuscripts are to be double-spaced and formatted using the same font, size 12 throughout text and references.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Keywords: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 250 words. Except for reviews, abstracts should be structured as follows:

Background/Aims: What is the major problem that prompted the study?

Methods: How was the study performed?

Results: Most important findings?

Conclusion: Most important conclusion?

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Average table = 250 words.
The maximum size of all uploaded files is 40 MB.

Color Illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References

In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, cite all authors. Abbreviate journal names according to the Index Medicus system. (Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interferon-gamma-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpg).

Author’s Choice

Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/policy.htm

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page charges

There are no page charges for papers of 5 printed pages. Each additional complete or partial page will be charged to the author at the rate of CHF 325.00 per page.

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

KARGER

© 2012 S. Karger AG, Basel
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

The Guidelines for Authors are available at: www.karger.com/crm_Guidelines

Downloaded by: 54.70.40.11 - 11/7/2017 2:13:23 AM
A collection of extraordinary essays on key issues in the natural sciences

GOTTFRIED SCHATZ

A MATTER OF WONDER

WHAT BIOLOGY REVEALS ABOUT US, OUR WORLD, AND OUR DREAMS

Where do we come from? Is our destiny determined by the genes we inherit? Do we all see the same blue color when we look at the sky? In this book Gottfried (Jeff) Schatz, the world-renowned biochemist, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mystery of life. The key to understanding life is to be found in its chemistry, and he proves that this is no dry endeavor and certainly not devoid of beauty. The result is a collection of eloquently and poetically written essays dealing with key issues in the natural sciences. It will appeal not only to scientists, but also to all inquisitive minds, regardless of educational and professional background.

Schatz, G. (Basel)
A Matter of Wonder
What Biology Reveals about Us, Our World, and Our Dreams
XII + 190 p., 2 color fig., hard cover, 2011
CHF 29.– / EUR 21.50 / USD 29.00
Prices subject to change
EUR price for Germany, USD price for USA only

More information and sample essays at www.karger.com/schatz

Orders can be placed at agencies, bookstores or directly with the publisher.
Also available through Amazon.com.

‘A collection of extraordinary essays, reminiscent in many ways – scope, erudition, clarity, occasional whimsicality and sassiness – of Stephen Jay Gould’s essays for Natural History’
Herbert Deinert (Cornell University, Ithaca, N.Y.)

‘A remarkable fusion of science and humanism’
Eugene P. Kennedy (Harvard University, Boston, Mass.)
Contents

See the journal website for contents
THE ACADEMY FOR CLINICAL DEBATES & CONTROVERSIES IN MEDICINE

CODHy

The 4th World Congress on
CONTROVERSIES TO CONSENSUS IN DIABETES, OBESITY AND HYPERTENSION

BARCELONA, SPAIN • NOVEMBER 8-11, 2012

CO-CHAIRPERSONS
S. Del Prato, Italy | I. Raz, Israel

PROGRAM DIRECTOR
P. Home, UK

ORGANIZING COMMITTEE
J. Chan, Hong Kong
J. Davidson, USA
R.A. DeFronzo, USA
E. Grossman, Israel
P. Home, UK
M. Laakso, Finland
L.A. Leiter, Canada
E. Standl, Germany
L. Van Gaal, Belgium

ABSTRACT SUBMISSION DEADLINE: AUGUST 15, 2012

www.codhy.com • codhy@codhy.com
A roadmap for the safe and effective use of therapeutic agents with 1,504 drugs and 2,133 references!

G. Seyffart

Seyffart’s Directory of Drug Dosage in Kidney Disease

2011. X, 870 pages
1,504 drugs and 2,133 references
ISBN 978-3-87185-400-2
EUR 110.00 / US$ 135.00 + shipping

The management of patients with renal impairment is a challenge. Such patients frequently have multiple system involvement and require appropriate therapy, but renal impairment affects drug metabolism and makes drug interactions likely.

The author, Dr. Günter Seyffart, has had a lifelong interest in this subject and has contributed in very important ways to our current understanding of how drugs can be more safely used in patients with kidney disease. In this directory about 1500 drugs are covered with very specific recommendations (contraindications dosage modifications, and potential nephrotoxicity) concerning use in patients with kidney disease. Such a comprehensive guide, written by an experienced clinical nephrologist, is an invaluable tool for the physician seeking to minimize the risks and optimize the benefits of therapeutic agents in patients with kidney disease of varying severity (as approximated by estimates of the prevailing level of GFR). The systematic approach taken provides not only clarity of exposition but also greatly enhances the practical utility of the Directory. This Directory will help to avoid catastrophes and modulate the risk of adverse events due to drug use in patients with kidney disease. Prevention is an often used byword in medicine – this monograph brings prevention to the bedside.
The journal of 'CardioRenal Medicine' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues. Attention is paid to the fact that some disorders associated with the metabolic syndrome cluster with albuminuria and chronic kidney disease. Moreover, certain metabolic abnormalities of the heart promote impaired coronary artery endothelial function, diastolic dysfunction and ischemic reconditioning. Another point of focus is the role of the obesity epidemic in promoting the increasing incidence of kidney disease and diastolic heart failure in industrialized countries, and the prevailing problems of insufficient exercise and excessive consumption of cheap, unwholesome food in promotion of the cardiorenal metabolic syndrome in both adults and children.

'CardioRenal Medicine' addresses a multidisciplinary audience consisting of nephrologists, cardiologists, nutritionists, endocrinologists, physiologists and general internists.

Selected contributions
The Heart and the Kidneys: Partners in Disease? Sowers, J.R. (Columbia, Mo.)
Effects of Chronic Antagonism of Endocannabinoid-1 Receptors on Glucose Tolerance and Insulin Action in Skeletal Muscles of Lean and Obese Zucker Rats: Indborg, K.A. (Tucson, Ariz.); Jacob, S. (Villingen-Schwenningen); Henriksen, E.J. (Tucson, Ariz.)
Interaction between Adiponectin and Aldosterone: Flynn, C.; Bakris, G.L. (Chicago, Ill.)
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney: Pulakat, L.; DeMarco, V.G.; Whaley-Connell, A.; Sowers, J.R. (Columbia, Mo.)
An Emerging Role for Understanding Orthostatic Hypertension in the Cardiorenal Syndrome: Buddineni, J.P.; Chauhan, L.; Ahsan, S.T.; Whaley-Connell, A. (Columbia Mo.)

More information at www.karger.com/crm
- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation
11 Ultrasonography: Ariadne’s Thread in the Diagnosis of the Cardiorenal Syndrome
Di Lullo, L. (Tivoli); Floccari, F. (Civitavecchia); Granata, A. (Catania); D’Amelio, A. (Lecce); Rivera, R. (Monza); Fiorini, F. (Rovigo); Malaguti, M. (Civitavecchia); Timio, M. (Foligno)

1 Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study
Dwyer, J.P. (Nashville, Tenn.); Parving, H.-H. (Copenhagen/Aarhus); Hunsicker, L.G. (Iowa City, Iowa); Ravid, M. (Tel Aviv); Remuzzi, G. (Bergamo); Lewis, J.B. (Nashville, Tenn.) for the DEMAND Investigators

18 Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?
Di Lullo, L. (Tivoli); Floccari, F. (Civitavecchia); Granata, A. (Agrigento); Malaguti, M. (Civitavecchia)

26 Adjusting for Urinary Creatinine Overestimates Arsenic Concentrations in Diabetics

33 Cardiorenal Syndrome Type 1 May Be Immunologically Mediated: A Pilot Evaluation of Monocyte Apoptosis
Virzi, G.M.; Torregrossa, R.; Cruz, D.N.; Chionh, C.Y.; de Cal, M.; Soni, S.S. (Vicenza); Dominici, M. (Modena); Vescovo, G. (Vicenza); Rosner, M.H. (Charlottesville, Va.); Ronco, C. (Vicenza)

43 The Relationship between Epicardial Adipose Tissue and Coronary Artery Calcification in Peritoneal Dialysis Patients
Turkmen, K.; Ozbek, O.; Kayikcioğlu, H.; Kayrak, M.; Solak, Y.; Nayman, A.; Anil, M.; Babur, H.; Tonbul, H.Z. (Meram)

52 A Case of Carcinoid Tumor-Associated Hypercalcemia
Siyam, F.; Abdullah, O.; Gardner, M.; Brietzke, S.; Sowers, J. (Columbia, Mo.)

57 Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease
Wang, X.; Belani, S.; Coyne, D.W.; Fabbrini, E.; Reeds, D.N.; Patterson, B.W.; Mittendorfer, B.; Klein, S. (St. Louis, Mo.)

66 Ultrastructure Study of Transgenic Ren2 Rat Aorta – Part 1: Endothelium and Intima